

SETTLEMENT AGREEMENT AND RELEASE

I. PREAMBLE

As a preamble to this AGREEMENT, the PARTIES agree to the following:

- A. The PARTIES to this Settlement Agreement and Release (the “AGREEMENT”) are (i) the STATE, as defined in Section II.A, (ii) the RELATORS, as defined in Section II.C, and (iii) the DEFENDANT, as defined in Section II.B. In this AGREEMENT, (a) the STATE and the RELATORS are referred to collectively as “PLAINTIFFS”; and (b) the STATE, RELATORS, and DEFENDANT are each individually referred to as a “PARTY” and collectively referred to as the “PARTIES.”
- B. The RELATORS filed the following action against the DEFENDANT: *The State of Texas, ex rel. SCEF, LLC v. AstraZeneca Pharmaceuticals LP*, Cause No. D-1-GN-25-011002, Travis County District Court, State of Texas.
- C. This AGREEMENT is the result of the PARTIES’ compromise on disputed issues of fact and law and is neither an admission of facts, wrongdoing, fault, contravention of any law, potential violation of law, misrepresentation, misdeeds, or liability by the DEFENDANT nor a concession by the PLAINTIFFS that their allegations, claims, and representations are not well-founded.
- D. As a result of a mutual desire to settle their disputes amicably and to avoid the delay, expense, litigation costs, inconvenience, and uncertainty of protracted litigation, the PARTIES have reached a full and final settlement of the PLAINTIFFS’ claims, and any potential claims arising from the COVERED CONDUCT, as set forth and defined in this AGREEMENT.

- E. The DEFENDANT has defenses to the PLAINTIFFS' claims and has denied and continues to deny the PLAINTIFFS' allegations or any wrongdoing or misrepresentation as may be alleged by the PLAINTIFFS. For avoidance of doubt, the DEFENDANT has denied and continues to deny the PLAINTIFFS' characterization or naming convention of any of the programs, including "Free Nurse Program," "Support Services Program," and "White Coat Marketing Program."
- F. The STATE has concluded that the settlement, as set forth in this AGREEMENT, is in the public interest and is fair, adequate, and reasonable under all the circumstances.
- G. The RELATORS agree that the settlement, as set forth in this AGREEMENT, is fair, adequate, and reasonable under all the circumstances.
- H. This AGREEMENT becomes effective on the EFFECTIVE DATE as defined in Section II.F.

II. DEFINITIONS

This AGREEMENT uses the following definitions:

- A. "STATE" means collectively the State of Texas, its past, present, and successor officers, agents, entities, divisions, agencies, commissions, departments, administrators, employees, attorneys, and legal representatives.
- B. "DEFENDANT" means AstraZeneca Pharmaceuticals LP.
- C. "RELATORS" means SCEF, LLC, and Lynne Levin-Guzman.
- D. "RELEASED PARTIES" collectively means the DEFENDANT and each of its past, present, acquired, predecessor, and successor companies, parents, subsidiaries,

affiliates, entities, divisions, officers, directors, members, partners, limited partners, principals, assigns, employees, owners, shareholders, insurers, and attorneys.

- E. “LAWSUIT” means the action commenced by the RELATORS against the DEFENDANT, captioned *The State of Texas, ex rel. SCEF, LLC v. AstraZeneca Pharmaceuticals LP*, Cause No. D-1-GN-25-011002, Travis County District Court, State of Texas.
- F. “EFFECTIVE DATE” means the date of signature of the last signatory to this AGREEMENT.
- G. “COVERED DRUGS” means the AstraZeneca pharmaceutical products identified in Attachment A to this AGREEMENT.
- H. “COVERED CONDUCT” means the conduct and actions alleged in the LAWSUIT arising from the DEFENDANT’s operation of the following programs with respect to the COVERED DRUGS during the SPECIFIED TIME PERIOD: (i) the **Free Nurse Program** — the offer and/or provision of free nursing services or patient management services to prescribers, healthcare professionals, and patients as in-kind remuneration; (ii) the **Support Services Program** — the assumption of reimbursement and administrative support services that prescribers perform for their patients; and (iii) the **White Coat Marketing Program** — the provision of remuneration to third parties to deploy clinical nurse educators and other healthcare professionals to recommend AstraZeneca products to prescribers, healthcare professionals, and patients. The foregoing programs are alleged to constitute illegal remuneration under the THFPA and TAKS, designed to induce prescriptions for AstraZeneca products covered by Texas Medicaid.

- I. “SPECIFIED TIME PERIOD” means any time on or before the EFFECTIVE DATE.
- J. “THFPA” means the Texas Health Care Program Fraud Prevention Act, Tex. Hum. Res. Code ch. 36.
- K. “TAKS” means the Texas Anti-Kickback Statute, Tex. Hum. Res. Code § 32.039.

III. AGREEMENT

NOW, THEREFORE, in reliance on the representations in this AGREEMENT; in consideration of the mutual promises, covenants, and obligations set forth in this AGREEMENT; and for good and valuable consideration as stated in this AGREEMENT, the PARTIES agree as follows:

- A. The foregoing Definitions and Preamble are incorporated herein.
- B. The DEFENDANT shall make payment to the STATE of \$33,998,000.00 (the “SETTLEMENT AMOUNT”) as non-punitive compensation in full and final settlement of the LAWSUIT and COVERED CONDUCT, and all claims that the STATE had, has, or may have in the future arising from the COVERED CONDUCT. The SETTLEMENT AMOUNT specifically includes all attorneys’ fees for the STATE and specifically excludes attorneys’ fees and expenses for the RELATORS (the “RELATORS’ FEES”).
 - 1. For purposes of and in accordance with Section 162(f)(2)(A) of the United States Internal Revenue Code, \$22,948,650 of the SETTLEMENT AMOUNT is restitution. The Parties agree that this characterization reflects the nature of the payment at the time of this agreement. In all other respects, the DEFENDANT expressly acknowledges and agrees that it is not entitled

to direct or influence how the STATE allocates the SETTLEMENT AMOUNT.

2. The STATE will allocate and distribute to the United States Government a pro rata share of the SETTLEMENT AMOUNT in accordance with state and federal law.
3. The PARTIES agree that the SETTLEMENT AMOUNT shall constitute a full and complete satisfaction by the DEFENDANT and the RELEASED PARTIES of any remedy, restitution, amount, payment or overpayment owed, or that could be owed, or other losses sustained or incurred, arising from the COVERED CONDUCT, and that neither the STATE nor the RELATORS shall be entitled to any additional amounts or recoveries from the DEFENDANT or any of the RELEASED PARTIES for the COVERED CONDUCT.

- C. Within twenty-one (21) business days of the EFFECTIVE DATE of this AGREEMENT, and in accordance with wiring instructions provided by the Office of the Attorney General of Texas, the DEFENDANT shall pay the STATE the SETTLEMENT AMOUNT. If the DEFENDANT does not pay the SETTLEMENT AMOUNT by 5:00 p.m. (Central Standard Time) within twenty-one (21) business days of the EFFECTIVE DATE, then the SETTLEMENT AMOUNT will begin to accrue interest at a 10.00% annual rate from the twenty-second business day following the EFFECTIVE DATE until the DEFENDANT pays the SETTLEMENT AMOUNT plus accrued interest. The PARTIES will cooperate to exchange wiring instructions and routing instructions so that such payment can be promptly made, and notwithstanding

the above deadlines for payment, no payment shall be made until such wiring and routing instructions have been provided.

- D. With respect to any other actions initiated by a private person pursuant to Tex. Hum. Res. Code § 36.101 et seq., the STATE and the DEFENDANT agree that the STATE shall be solely responsible to pay RELATORS' or RELATORS' counsel for RELATORS' share pursuant to Tex. Hum. Res. Code 36.110 and that none of the RELEASED PARTIES shall have any responsibility to pay any such amounts in any manner for the COVERED CONDUCT awarded or agreed to be paid to such relators or their counsel. The STATE agrees and commits to resolving any such amounts using the proceeds paid to the STATE under this AGREEMENT. This excludes RELATORS' FEES which shall be paid separately by the RELEASED PARTIES.
- E. The DEFENDANT agrees to submit to the jurisdiction of the Travis County District Court, State of Texas in this or any other action or proceeding arising out of or relating to this AGREEMENT, the enforcement hereof, or the transactions contemplated hereby. Within three (3) business days of the STATE's receipt of the SETTLEMENT AMOUNT, the STATE and RELATORS shall file a non-suit with prejudice dismissing the LAWSUIT.
- F. In exchange for the consideration described herein (including payment of the SETTLEMENT AMOUNT), the STATE, as of the EFFECTIVE DATE, fully and finally, and to the greatest extent allowed by law, releases, discharges, and covenants not to sue the RELEASED PARTIES for any civil, regulatory, and/or administrative or other claim, action, suit, demand, right, cause of action, liability, judgment, damage, loss, or proceeding (including, without limitation, remedies, restitution, damages,

attorneys' fees, expert and consultant fees, fines, penalties, costs, interest, and expenses of every kind and however denominated) the STATE or the RELATORS have asserted, may have asserted, or could have asserted under any source of law, contract, in equity or other right, in any manner for the COVERED CONDUCT. In addition, the STATE agrees that it will not initiate, prosecute, direct, recommend, or maintain any action or other proceeding, including by way of example and not limitation, civil investigative demands, against the RELEASED PARTIES for the COVERED CONDUCT on behalf of itself, a *qui tam* relator, the United States, or any other person or entity. In addition, the STATE agrees that it will not initiate, prosecute, direct, recommend, or maintain any action or proceeding against the RELEASED PARTIES seeking exclusion from the Texas Medicaid Program or any other administrative action or sanction for the COVERED CONDUCT. This AGREEMENT is not intended to release claims or causes of action that do not involve the COVERED CONDUCT or are unrelated thereto.

- G. In exchange for the consideration described herein (including payment in full of the SETTLEMENT AMOUNT), the RELATORS, and their past and present acquired or predecessor companies, parents, subsidiaries, affiliates, entities, divisions, officers, directors, members, partners, limited partners, principals, employees, owners, and shareholders (including but not limited to NHCA Group, Venari Partners, and any past, existing or future affiliate thereof), as of the EFFECTIVE DATE, fully and finally, and to the greatest extent allowed by law, release, discharge, and covenant not to sue the RELEASED PARTIES for any criminal, civil, regulatory, and/or administrative or other claim, action, suit, demand, right, cause of action, liability, judgment, damage,

loss, or proceeding (including, without limitation, remedies, restitution, damages, attorneys' fees, expert and consultant fees, fines, penalties, costs, interest, and expenses of every kind and however denominated) the STATE or the RELATORS have asserted, may have asserted, or could have asserted under any source of law, contract, in equity or other right, in any manner for the COVERED CONDUCT. Notwithstanding the above, RELATORS do not release in this AGREEMENT any claims for expenses, attorneys' fees, and costs pursuant to Tex. Hum. Res. Code § 36.110(c).

- H. The DEFENDANT, and its past and present acquired or predecessor companies, parents, subsidiaries, affiliates, entities, divisions, officers, directors, members, partners, limited partners, principals, employees, owners, and shareholders, fully and finally, and to the greatest extent allowed by law, as of the EFFECTIVE DATE, releases the STATE from any claims based on events occurring prior to the EFFECTIVE DATE (including attorneys' fees, costs, and expenses of every kind and however denominated) which the DEFENDANT has asserted, may have asserted, could have asserted, or may assert in the future against the STATE, for the COVERED CONDUCT and the STATE's investigation and prosecution thereof. Further, the DEFENDANT, and its past and present acquired or predecessor companies, parents, subsidiaries, affiliates, entities, divisions, officers, directors, members, partners, limited partners, principals, employees, owners, and shareholders, as of the EFFECTIVE DATE, fully and finally releases the RELATORS and their past, present, acquired, predecessor, and successor companies, parents, subsidiaries, affiliates, entities, divisions, officers, directors, members, partners, limited partners, principals, assigns, employees, owners, shareholders, insurers, and attorneys from any claims based on

events occurring prior to the EFFECTIVE DATE (including attorneys' fees, costs, and expenses of every kind and however denominated) which the DEFENDANT asserted, could assert, or may assert in the future against the RELATORS for the COVERED CONDUCT and the investigation and prosecution thereof.

- I. The PARTIES agree that not later than sixty (60) days after the EFFECTIVE DATE, each PARTY shall return all Discovery Material of a Producing Party (as defined in the Protective Order governing the LAWSUIT) to the respective counsel of the Producing Party or destroy such Discovery Material, at the option of the Producing Party (provided written confirmation is provided to the Producing Party).
- J. Notwithstanding any other terms of this AGREEMENT, including the releases in Paragraphs III.F., III.G., and III.H. above, all of the following are specifically reserved and excluded from the scope and terms of this AGREEMENT, and from the scope and terms of the Releases, as to any entity or person, including the PARTIES:
 1. Any claim based upon an obligation created by this AGREEMENT or any breach hereof;
 2. Any claim based upon an express or implied product or service warranty claim or for defective or deficient products or services the DEFENDANT provided;
 3. Any claim the STATE may assert, including claims on behalf of individual consumers, or state program payors, against any person or entity, including any of the RELEASED PARTIES, under any statute, regulation, or rule not covered by the release in Paragraph III.F. above, including but not limited to, claims for any and all of the following: (i) state or federal antitrust violations; or (ii) unfair or deceptive acts and practices or violations of consumer protection laws;

4. Any claim related to product safety or efficacy misrepresentations not encompassed by the COVERED CONDUCT;
 5. The subrogation rights to claims for personal injury or property damage arising from usage of any of the DEFENDANT's products by a participant in the Medicaid Program;
 6. Any claim based on a failure by the DEFENDANT to deliver products or services due;
 7. Any claim arising from the DEFENDANT's obligation to pay rebates to the STATE under any law or contract, including, but not limited to, under the provisions of the Omnibus Budget Reconciliation Act of 1990 ("OBRA 90");
 8. Any criminal liability not specifically released by this AGREEMENT;
 9. Any civil, criminal, or administrative liability arising under Title 26, U.S. Code (Internal Revenue Code) or any state tax or revenue law; or
 10. Any liability to the STATE for any conduct other than the COVERED CONDUCT.
- K. This AGREEMENT is intended to be solely for the benefit of the PARTIES and persons and entities released and, except as stated herein, the PARTIES do not by this instrument release any claims against any other person or entity. No word, term, phrase, or definition in this AGREEMENT is or may be used for the benefit of any person, entity or litigant who is not a signatory to, or released by this AGREEMENT.
- L. The PLAINTIFFS hereby agree that this AGREEMENT, and any and all negotiations, documents, and discussions associated with this AGREEMENT shall be without

prejudice to the rights of any PARTY, shall not be deemed or construed to be an admission or evidence of any violation of any statute or law or any potential violation of law, or of any liability or misrepresentation or wrongdoing by the RELEASED PARTIES or of the truth or the infirmity of any of the claims or allegations of the PLAINTIFFS, and evidence thereof shall not be discoverable or used directly or indirectly by PLAINTIFFS in any way (unless otherwise stated herein and except that the provisions of this AGREEMENT may be used by the PARTIES to enforce its terms), whether in Texas or in any other forum. PLAINTIFFS agree that they will not urge or seek to admit this AGREEMENT as evidence of any fault or liability of the RELEASED PARTIES in any investigation, administrative claim, action, suit or proceeding, or federal or state court or arbitration proceeding.

- M. Nothing in this AGREEMENT is a waiver of the STATE's sovereign immunity, except as to a proceeding to enforce this AGREEMENT, and as to any such proceeding to enforce this AGREEMENT, the STATE acknowledges that sovereign immunity has been waived.
- N. Any PARTY may enforce the terms of this AGREEMENT in the District Courts of Travis County, Texas, which shall have exclusive jurisdiction and venue over any such action.
- O. With the exception of RELATORS' FEES which shall be paid by DEFENDANT to RELATORS under separate Agreement, this AGREEMENT constitutes the complete agreement among the STATE, RELATORS, and DEFENDANT with regard to the settlement of the LAWSUIT as to all PARTIES. This AGREEMENT may not be amended or modified as to all PARTIES except by a writing signed by all PARTIES.

- P. Except as otherwise agreed to in writing, each Party will bear its own legal and other costs incurred in connection with the LAWSUIT, including the preparation and performance of this AGREEMENT.
- Q. This AGREEMENT shall be governed by the laws of the State of Texas.
- R. If any provision of this AGREEMENT, or the application thereof, shall for any reason or to any extent be construed by a court of competent jurisdiction to be invalid or unenforceable, the remainder of this AGREEMENT, and application of such provision to other circumstances, shall remain in effect and be interpreted so as best to reasonably effect the intent of the PARTIES, which is to resolve the dispute between the PARTIES regarding the COVERED CONDUCT as set forth in the LAWSUIT.
- S. None of the PARTIES to this AGREEMENT shall be considered the drafter of this AGREEMENT or of any included provision for the purpose of any statute, case law, or rule of construction that would or might cause any provision to be construed against the drafter.
- T. DEFENDANT expressly warrants that it has reviewed its financial condition and that it is currently solvent within the meaning of 11 U.S.C. §§ 547(b)(3) and 548(a)(1)(B)(ii)(I) and believes that it shall remain solvent upon payment of the SETTLEMENT AMOUNT and compliance with this AGREEMENT.
- U. Each Party represents that it freely and voluntarily enters this AGREEMENT without any degree of duress whatsoever.
- V. Any notice required or permitted to be delivered hereunder shall be deemed received:
(i) five (5) calendar days thereafter sent by United States Mail, postage prepaid,

certified mail, return receipt requested, addressed to the PARTY at the address set forth below (or such other address as such PARTY may subsequently designate in writing); (ii) on the day actually received if sent by courier or otherwise hand delivered; or (iii) when sent, if sent by electronic mail during business hours (9:00 a.m. CST to 5:00 p.m. CST, Monday through Friday), and if not sent during normal business hours, then on the next business day. Unless otherwise stated in writing subsequent to the EFFECTIVE DATE, all notifications and communications made pursuant to this AGREEMENT shall be submitted to the persons or entities listed below:

The STATE, for all purposes:

Office of the Attorney General of Texas
Amy Hilton
Chief, Healthcare Program Enforcement Division
Assistant Attorney General
P.O. Box 12548
Austin, Texas 78711-2548
Phone: (512) 936-1709
Fax: (512) 499-0712
Email: amy.hilton@oag.texas.gov

RELATOR SCEF, LLC, and LYNNE LEVIN-GUZMAN for all purposes:

W. Mark Lanier
Alex J. Brown
Zeke DeRose III
The Lanier Firm, P.C.
10940 W. Sam Houston Pkwy N, Suite 300
Houston, TX 77064
Telephone: (713) 659-5200
Facsimile: (713) 659-2204
E-Mail: wml@lanierlawfirm.com
Alex.Brown@lanierlawfirm.com
Zeke.DeRose@lanierlawfirm.com

Jennifer L. Truelove
McKool Smith, P.C.

104 East Houston, Suite 300
Marshall, TX 75670
Telephone: (903) 923-9000
Facsimile: (903) 923-9099
E-Mail: jtruelove@mckoolsmith.com

DEFENDANT, for all purposes:

AstraZeneca U.S. Legal Department
legalnotices@astrazeneca.com

Kevin Jayne
Senior Counsel
AstraZeneca Pharmaceuticals LP
1800 Concord Pike
Wilmington, DE 19803
Telephone: (800) 456-3669
E-Mail: kevin.jayne@astrazeneca.com

Ryan P. McCarthy
Morgan Lewis LLP
2222 Market Street
Philadelphia, PA 19103
Telephone: (215) 963.5412
E-Mail: ryan.mccarthy@morganlewis.com

Paul Singer
Kelley Drye & Warren LLP
670 Maine Avenue SW, Suite 600
Washington, DC 20024
Telephone: (202) 342-8672
E-Mail: psinger@kelleydrye.com

W. The PARTIES have read the AGREEMENT and accept and agree to the provisions contained herein and have caused this AGREEMENT to be signed as of the day and date adjacent to their respective signatures. The individual signing this AGREEMENT on behalf of DEFENDANT represents and warrants that

DEFENDANT authorizes him or her to execute this AGREEMENT. The individual signing this AGREEMENT on behalf of the RELATOR represents and warrants that the RELATORS authorize him or her to execute this AGREEMENT. The undersigned STATE signatories represent that they are signing this AGREEMENT in their official capacities and that they are authorized to execute this AGREEMENT and to compromise the claims of the STATE.

X. The PARTIES represent and acknowledge that in entering into this AGREEMENT they are not relying on any promises or representations other than those expressly set forth in this AGREEMENT. The PARTIES understand, acknowledge, and agree that (i) they have each performed an independent investigation of the allegations of fact and law surrounding this matter; and (ii) they each may hereafter discover facts in addition to, or different from, those that they now know or believe to be true with respect to the subject matter of this AGREEMENT. Nevertheless, it is the PARTIES' intention to resolve their disputes pursuant to the terms of this AGREEMENT and thus, in furtherance of their intentions, the AGREEMENT shall remain in full force and effect notwithstanding the discovery of any additional facts or law, or changes in law, and the AGREEMENT shall not be subject to rescission or modification by reason of any such discovery or change.

Y. The waiver of any rights conferred by this AGREEMENT shall be effective only if made in writing by the waiving PARTY. The waiver by any PARTY of any breach of this AGREEMENT shall not be deemed or construed as a waiver of any other breach, whether before, after, or contemporaneously with this AGREEMENT.

- Z. This AGREEMENT may be executed in counterparts, each of which shall constitute an original and all of which shall constitute one and the same AGREEMENT. Faxed, emailed, and portable document format (“PDF”) signatures will suffice.
- AA. Each PARTY agrees to perform such further acts and to execute and to deliver such further documents as may reasonably be necessary to carry out this AGREEMENT.
- BB. The DEFENDANT may not assign or transfer any of its rights or delegate its duties under this AGREEMENT, except with the prior written consent of the STATE.
- CC. If any one of the PARTIES is required to obtain the services of an attorney to enforce this AGREEMENT, the prevailing party, in addition to other remedies available, shall be entitled to recover its reasonable attorneys’ fees, costs, and costs of court.
- DD. All the terms of this AGREEMENT shall apply to and shall be binding upon and inure to the benefit of the PARTIES and their respective successors and assigns.

STATE OF TEXAS

Office of the Attorney General

By: Amy Hilton

Date: 6/24/2026 | 11:30 AM CDT

Amy Hilton

Healthcare Program Enforcement Division at Texas Attorney General

Assistant Attorney General

Office of the Attorney General of Texas

P.O. Box 12548

Austin, Texas 78711-2548

Texas Health & Human Services Commission

By: Karen Ray

Digitally signed by Karen Ray
Date: 2026.06.23 09:29:10
+05'00'

Date: _____

Karen Ray, Chief Counsel

Texas Health & Human Services Commission

4601 W. Guadalupe Street

Austin, TX 78751

DEFENDANT

AstraZeneca Pharmaceuticals LP

By: _____

Date: _____

Mariam Koohdary

Authorized Signatory

Deputy General Counsel North America & Secretary

COUNSEL FOR DEFENDANT

By: _____

Date: _____

Ryan P. McCarthy

John C. Dodds

Morgan Lewis LLP

2222 Market Street

Philadelphia, PA 19103

STATE OF TEXAS

Office of the Attorney General

By: _____

Date: _____

Amy Hilton

Healthcare Program Enforcement Division at Texas Attorney General

Assistant Attorney General

Office of the Attorney General of Texas

P.O. Box 12548

Austin, Texas 78711-2548

Texas Health & Human Services Commission

By: _____

Date: _____

Karen Ray, Chief Counsel


Texas Health & Human Services Commission

4601 W. Guadalupe Street

Austin, TX 78751

DEFENDANT

AstraZeneca Pharmaceuticals LP

By:  _____


Date: 6/10/2020

Mariam Koohdary

Authorized Signatory

Deputy General Counsel North America & Secretary

COUNSEL FOR DEFENDANT

By:  _____

Date: 6/18/2020

Ryan P. McCarthy

John C. Dodds

Morgan Lewis LLP

2222 Market Street

Philadelphia, PA 19103

By: Paul Singer

Date: 6/17/2026

Paul Singer

Kelley Drye & Warren LLP

670 Maine Avenue SW, Suite 600

Washington, DC 20024

RELATOR SCEF, LLC

By: _____

Date: _____

RELATOR LYNNE LEVIN-GUZMAN

By: _____

Date: _____

COUNSEL FOR RELATORS

By: _____

Date: _____

W. Mark Lanier

Alex J. Brown

Zeke DeRose III

The Lanier Firm, P.C.

10940 W. Sam Houston Pkwy N, Suite 300

Houston, TX 77064

By: _____

Date: _____

Jennifer L. Truelove

McKool Smith, P.C.

104 East Houston, Suite 300

Marshall, TX 75670

By: _____

Date: _____

Paul Singer

Kelley Drye & Warren LLP

670 Maine Avenue SW, Suite 600

Washington, DC 20024

RELATOR SCEFF, LLC

By: _____

Date: _____
John Minimo, Managing Member
6-18-26

RELATOR LYNNE LEVIN-GUZMAN

By: _____

Date: _____

COUNSEL FOR RELATORS

By: _____

Date: _____

W. Mark Lanier

Alex J. Brown

Zeke DeRose III

The Lanier Firm, P.C.

10940 W. Sam Houston Pkwy N, Suite 300

Houston, TX 77064

By: _____

Date: _____

Jennifer L. Truelove

McKool Smith, P.C.

104 East Houston, Suite 300

Marshall, TX 75670

By: _____

Date: _____

Paul Singer

Kelley Drye & Warren LLP

670 Maine Avenue SW, Suite 600


Washington, DC 20024

RELATOR SCEF, LLC

By: _____

Date: _____

RELATOR LYNNE LEVIN-GUZMAN

By: 

Date: 6/11/20

COUNSEL FOR RELATORS

By: _____

Date: _____

W. Mark Lanier

Alex J. Brown

Zeke DeRose III

The Lanier Firm, P.C.

10940 W. Sam Houston Pkwy N, Suite 300

Houston, TX 77064

By: _____

Date: _____

Jennifer L. Trulove

McKool Smith, P.C.

104 East Houston, Suite 300

Marshall, TX 75670

By: _____

Date: _____

Paul Singer

Kelley Drye & Warren LLP

670 Maine Avenue SW, Suite 600

Washington, DC 20024

RELATOR SCEF, LLC

By: _____

Date: _____

RELATOR LYNNE LEVIN-GUZMAN

By: _____

Date: _____

COUNSEL FOR RELATORS

By:  _____

Date: _____

W. Mark Lanier

Alex J. Brown

Zeke DeRose III

The Lanier Firm, P.C.

10940 W. Sam Houston Pkwy N, Suite 300

Houston, TX 77064

By: _____

Date: _____

Jennifer L. Truelove

McKool Smith, P.C.

104 East Houston, Suite 300

Marshall, TX 75670

By: _____

Date: _____

Paul Singer

Kelley Drye & Warren LLP

670 Maine Avenue SW, Suite 600

Washington, DC 20024

RELATOR SCEF, LLC

By: _____

Date: _____

RELATOR LYNNE LEVIN-GUZMAN

By: _____

Date: _____

COUNSEL FOR RELATORS

By: _____

Date: _____

W. Mark Lanier

Alex J. Brown

Zeke DeRose III

The Lanier Firm, P.C.

10940 W. Sam Houston Pkwy N, Suite 300

Houston, TX 77064

By:  _____

Date: 6/9/2022

Jennifer L. Truelove

McKool Smith, P.C.

104 East Houston, Suite 300

Marshall, TX 75670

Attachment A
Covered Drugs

Product
Brilinta
Bydureon
Calquence
Fasenra
Faslodex
FluMist Quadrivalent
Imfinzi
Imjudo
Iressa
Lokelma
Lumoxiti
Saphnelo
Symbicort
Tagrisso
Farxiga
Datroway
Koselugo
Lynparza
Tezspire